Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
272.11
+2.68 (0.99%)
Jan 17, 2025, 4:00 PM EST - Market closed
Amgen Employees
Amgen had 26,700 employees as of December 31, 2023. The number of employees increased by 1,500 or 5.95% compared to the previous year.
Employees
26,700
Change (1Y)
1,500
Growth (1Y)
5.95%
Revenue / Employee
$1,218,502
Profits / Employee
$158,427
Market Cap
146.27B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 26,700 | 1,500 | 5.95% |
Dec 31, 2022 | 25,200 | 1,000 | 4.13% |
Dec 31, 2021 | 24,200 | -100 | -0.41% |
Dec 31, 2020 | 24,300 | 900 | 3.85% |
Dec 31, 2019 | 23,400 | 1,900 | 8.84% |
Dec 31, 2018 | 21,500 | 700 | 3.37% |
Dec 31, 2017 | 20,800 | 1,600 | 8.33% |
Dec 31, 2016 | 19,200 | 1,300 | 7.26% |
Dec 31, 2015 | 17,900 | 0 | - |
Dec 31, 2014 | 17,900 | -2,100 | -10.50% |
Dec 31, 2013 | 20,000 | 2,000 | 11.11% |
Dec 31, 2012 | 18,000 | 200 | 1.12% |
Dec 31, 2011 | 17,800 | 400 | 2.30% |
Dec 31, 2010 | 17,400 | 200 | 1.16% |
Dec 31, 2009 | 17,200 | 300 | 1.78% |
Dec 31, 2008 | 16,900 | -600 | -3.43% |
Dec 31, 2007 | 17,500 | -2,600 | -12.94% |
Dec 31, 2006 | 20,100 | 3,600 | 21.82% |
Dec 31, 2005 | 16,500 | 2,100 | 14.58% |
Dec 31, 2004 | 14,400 | 1,500 | 11.63% |
Dec 31, 2003 | 12,900 | 2,800 | 27.72% |
Dec 31, 2002 | 10,100 | 2,400 | 31.17% |
Dec 31, 2001 | 7,700 | 400 | 5.48% |
Dec 31, 2000 | 7,300 | 900 | 14.06% |
Dec 31, 1999 | 6,400 | 900 | 16.36% |
Dec 31, 1998 | 5,500 | 192 | 3.62% |
Dec 31, 1997 | 5,308 | 662 | 14.25% |
Dec 31, 1996 | 4,646 | 600 | 14.83% |
Dec 31, 1995 | 4,046 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
AMGN News
- 3 days ago - FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER - PRNewsWire
- 3 days ago - US FDA approves Amgen's colorectal cancer therapy - Reuters
- 6 days ago - Amgen Inc. (AMGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 6 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 11 days ago - AMGEN TO PRESENT AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE - PRNewsWire
- 12 days ago - Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market - CNBC
- 12 days ago - Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer - Business Wire
- 14 days ago - Amgen: The Buying Opportunity Has Now Arrived (Rating Upgrade) - Seeking Alpha